Prestige Consumer Healthcare Inc.
NYSE•PBH
CEO: Mr. Ronald M. Lombardi CPA
Sector: Healthcare
Industry: Medical - Distribution
Listing Date: 2005-02-10
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers analgesic powders under the BC and Goody's brand; diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mouth pain under the Chloraseptic brand; eye care products that provide relief from redness and itchiness under the Clear Eyes brand name; at-home removal of common and plantar warts under the Compound W brand; and Debrox for ear wax removal. The company also provides dental guards, floss picks, interdental brushes, dental repair and kits, and tongue cleaners under the DenTek brand; Dramamine for motion sickness relief; enemas and other laxative products under the Fleet brand name; Gaviscon for upset stomach; cough drops under the Luden's brand; Monistat for yeast infections in women; Nix for lice and parasite treatments; feminine care products, including washes, cloths, and sprays under the Summer's Eve brand; TheraTears for dry eyes; nasal saline sprays and washes under the Fess brand name; and Hydralyte for oral rehydration. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.
Contact Information
660 White Plains Road, Suite 250, Tarrytown, NY, 10591, United States
914-524-6800
Market Cap
$2.93B
P/E (TTM)
15.7
31.2
Dividend Yield
--
52W High
$89.37
52W Low
$57.25
52W Range
Rank45Top 56.8%
3.6
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 3.6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q3 2026 Data
Revenue
$283.44M+0.00%
4-Quarter Trend
EPS
$0.98+0.00%
4-Quarter Trend
FCF
$75.26M+0.00%
4-Quarter Trend
2026 Q3 Earnings Highlights
Key Highlights
Quarterly Net Income Decline Net income $46.7M, down 23.5% for the quarter; diluted EPS fell to $0.97 from $1.22.
Completed Pillar5 Acquisition Acquired Pillar5 on December 18, 2025; preliminary goodwill recorded totaled $52.6M in the period.
Operating Cash Flow Stronger Nine-month operating cash flow increased to $214.8M, up $25.1M, driven by working capital timing.
Gross Margin Stable Quarterly gross profit margin held steady at 55.5% despite revenue decline of 2.4% to $283.4M.
Risk Factors
Supply Chain Disruptions Impact Continued shortages, delays, and backorders, particularly eye care products, negatively impacting sales results.
Rising Input Cost Pressure Volatile environment exacerbated rising input costs for raw materials, labor, and shipping impacting margins.
Customer Concentration Risk Dependence on limited customers; Walmart accounted for 18% of Q3 2025 gross revenues.
International Segment Gross Profit International segment gross profit dropped 11.6% quarterly due to inflation costs and unfavorable product mix.
Outlook
Liquidity Position Adequate Cash from operations and credit facilities expected to finance working capital and capital expenditures next twelve months.
Share Repurchase Authorization $92.9M remaining under the $300.0M common stock repurchase program authorized in May 2024.
Acquisition Integration Focus Management expects to finalize valuations for recent acquisitions, including Pillar5 and Feminax asset allocations.
Debt Covenants Compliance Management anticipates compliance with all financial and restrictive debt covenants over the next twelve months.
Peer Comparison
Revenue (TTM)
$4.25B
$2.23B
$2.16B
Gross Margin (Latest Quarter)
92.8%
90.8%
86.0%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| IMVT | $4.68B | -9.0 | -65.8% | 0.0% |
| INDV | $3.66B | 17.4 | -98.9% | 29.2% |
| CNTA | $3.64B | -15.0 | -67.7% | 26.4% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-1.5%
Flat Growth
4Q Net Income CAGR
-2.3%
Stable Profitability
Cash Flow Stability
100%
Strong Cash Flow
Deep Research
Next earnings:Apr 30, 2026
EPS:$1.39
|Revenue:$296.53M
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data